SCHEMBL998064

SCHEMBL998064

Cc1cccc(NC(=O)N2CCc3c([nH]c4ccccc34)C2=O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
LMNA P02545 2/20 0.55
KDM4E B2RXH2 2/20 0.55
HPGD P15428 2/20 0.55
CYP3A4 P08684 1/20 0.55
HTR1A P08908 1/20 0.55
CASP1 P29466 1/20 0.55
CASP7 P55210 1/20 0.55
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
TRPV1 Q8NER1 10/20 0.51
RAB9A P51151 3/20 0.50
NPC1 O15118 2/20 0.50
PDGFRB P09619 1/20 0.47
KDR P35968 1/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.46
TSHR P16473 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1000290 0.91 LMNA (0.57) ALDH1A1LMNAKDM4EHPGDCYP3A4
SCHEMBL998068 0.87 ALDH1A1 (0.60) ALDH1A1LMNAKDM4EHPGDCYP3A4
SCHEMBL998142 0.80 TRPV1 (0.78) TRPV1
SCHEMBL274447 0.77 NR1H4 (0.61) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL996814 0.76 TRPV1 (0.69) ALDH1A1TRPV1RAB9A
SCHEMBL1000695 0.76 TRPV1 (0.61) ALDH1A1LMNAKDM4ECYP3A4CASP1
SCHEMBL998477 0.76 OPRM1 (0.49) ALDH1A1LMNAMEN1KMT2ATRPV1
SCHEMBL12111749 0.74 KDM4E (0.61) ALDH1A1LMNAKDM4EHPGDCYP3A4
SCHEMBL9913668 0.73 KDM4E (0.65) ALDH1A1LMNAKDM4EHPGDCYP3A4
SCHEMBL997330 0.72 TP53 (0.66) LMNATRPV1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637521-B1 NOVEL TRICYCLIC HETEROCYCLE COMPOUND ONO PHARMACEUTICAL CO (JP) 2013-06-19 EP disclosed
US-7872133-B2 Tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-18 US disclosed
US-20060154944-A1 Novel tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154944-A1 Novel tricyclic heterocycle compound CYP11B1, CYP11B2, HCCS ALDH1A1 1422/4885LMNA 528/4885KDM4E 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.